TY - JOUR
AU - Nichols, Kim E.
AB - With recent advances in genomic technologies, decreasing costs, and increasing access, tumor and germline sequencing are increasingly being integrated into the medical care of children with cancer. Paired tumor–germline sequencing offers tremendous promise for optimizing pediatric cancer care by informing cancer treatment (e.g., via the use of molecularly targeted therapy), surveillance for subsequent malignancies, and implementation of cancer risk–reducing strategies (e.g., prophylactic surgery of at‐risk organs).1–3 However, fully benefiting from genomics necessitates that families understand the risks, limitations, and results of sequencing.In this issue of Cancer, Gereis et al.4 and McGill et al.5 prospectively examine parent and adolescent patient understanding and expectations of paired tumor–germline sequencing from consent through to germline results via a mixed‐methods design as part of the PRecISion Medicine for Children with Cancer trial (PRISM; a precision medicine trial assessing the feasibility and utility of somatic and germline sequencing for children with poor prognosis malignancies). Despite being provided written education about the trial, parents’ actual understanding of PRISM and the limitations of sequencing was relatively low after enrollment and the return of results. Parents endorsed higher perceived understanding than actual understanding, and their perceived and actual understanding were not significantly correlated, which suggests that parents may lack insight 
TI - Insights into parent and adolescent patient understanding of genomic sequencing
JF - Cancer
DO - 10.1002/cncr.34996
DA - 2023-11-15
UR - https://www.deepdyve.com/lp/wiley/insights-into-parent-and-adolescent-patient-understanding-of-genomic-Zka2cUvliM
SP - 3519
EP - 3521
VL - 129
IS - 22
DP - DeepDyve
ER -